GLP-1 Market
LLY $1137.82 ▲ +0.2% NVO $41.71 ▼ -1.9% PFE $27.46 ▼ -0.3% VKTX $29.52 ▼ -1.4% KLRA $12.70 ▼ -5.6% GPCR $35.50 ▼ -8.9% RHHBY $55.15 ▲ +0.4%
Market data delayed up to 20 min · Source: Twelve Data

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

HRS-4729

HRS-4729

Company
Fujian Shengdi Pharmaceutical Co., Ltd.
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
2 recruiting

Efficacy results: Not yet reported

Find a Clinical Trial Near Me

2 recruiting studies currently listed on ClinicalTrials.gov.

Data source: ClinicalTrials.gov · trial data as of Sep 17, 2026

Find a Clinical Trial Near Me

See recruiting studies for HRS-4729 and check eligibility with the study team.

Select conditions
Match
Treatment type

"Added to GLP-1" means the investigational treatment is being studied on top of an existing GLP-1-based therapy.

Your ZIP code is only used to calculate distance to trial sites — it isn't stored.

Trial details
  • Recruiting NCT NCT07660848

    A Study of HRS-4729 Injection and HRS9531 Injection in Participants With Metabolic Dysfunction-Associated Steatohepatitis

    Not yet reported Fujian Shengdi Pharmaceutical Co., Ltd. 160 participants Est. completion 2028-07 2 sites Stand-alone
    MASH
    View official trial listing →
  • Recruiting NCT NCT07807059

    A Single-Dose Pharmacokinetic Study of HRS-4729 Injection in Healthy Participants and Patients With Renal Impairment

    Not yet reported Fujian Shengdi Pharmaceutical Co., Ltd. 32 participants Est. completion 2027-03-15 1 site Stand-alone
    MASHMASLDType 2 diabetes Other conditions: Overweight/Obesity
    View official trial listing →
  • Completed NCT NCT06762600

    A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HRS-4729 Injection in Healthy Subjects

    Not yet reported Fujian Shengdi Pharmaceutical Co., Ltd. 102 participants Est. completion 2026-03-12 1 site Stand-alone
    Other conditions: Overweight or Obesity
    View official trial listing →
  • Not yet recruiting NCT NCT07690826

    A Study to Evaluate the Efficacy and Safety of HRS-4729 Injection in Obesity

    Not yet reported Fujian Shengdi Pharmaceutical Co., Ltd. 252 participants Est. completion 2027-07 1 site Stand-alone
    Other conditions: Overweight or Obesity
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources
Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.